Leukocyte Dysfunction in Diabetic Patients.

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sashwati Roy, The Ohio State University
ClinicalTrials.gov Identifier:
NCT01144520
First received: June 14, 2010
Last updated: August 21, 2014
Last verified: August 2014

June 14, 2010
August 21, 2014
March 2010
August 2015   (final data collection date for primary outcome measure)
Ex vivo leukocyte function by measuring ROS production [ Time Frame: immediately after blood draw ] [ Designated as safety issue: No ]
After blood draw monocytes are separated from whole blood and production of oxidants by these cells
Not Provided
Complete list of historical versions of study NCT01144520 on ClinicalTrials.gov Archive Site
Ex vivo NADPH oxidase gene and protein expression [ Time Frame: After blood draw ] [ Designated as safety issue: No ]
Gene and protein expressions are measured using Western blot and real time PCR.
Not Provided
Not Provided
Not Provided
 
Leukocyte Dysfunction in Diabetic Patients.
Leukocyte Dysfunction in Diabetic Patients.

The purpose of this study is to study impairment of white blood cell function in patients with type II diabetes.

Leucocytes from poorly controlled diabetes exhibit aberrant chemotaxis, increased susceptibility to bacterial infection, leukotriene production, lysosomal enzyme release, proinflammatory cytokine expression and production of reactive oxygen species. Aberrant glucose concentration in diabetics affects functions of peripheral blood system as well as the immune system leading to impaired host defense. Impaired wound healing is a serious complication associated with diabetes. We hypothesized that impairment in leukocyte function results in dysfunctional inflammatory response in diabetic wounds. The proposed studies focus on characterizing mechanisms that will improve our understanding of the dysfunctional inflammatory response resulting in non-healing chronic wounds in diabetics.

Observational
Not Provided
Not Provided
Retention:   Samples With DNA
Description:

Blood

Non-Probability Sample

Subjects will be recruited from the population who visit the Ohio State University (OSU) Hospitals and Comprehensive Wound Center (CWC), OSU Wexner Medical Center diabetic clinics and Bariatric clinic.

Diabetes Mellitus, Type 2
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
200
August 2015
August 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults ages 40-60 yrs old clinically diagnosed with Type II Diabetes
  • Adults ages 40-60 yrs old without Diabetes

Exclusion Criteria:

  • Unable to provide informed consent
  • Pregnant Females
  • Therapeutically Immuno-compromised
Both
40 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01144520
2009H0270
No
Sashwati Roy, The Ohio State University
Sashwati Roy
Not Provided
Principal Investigator: Roy Sashwati, MS, PhD Ohio State University Dept of Surgery
Ohio State University
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP